BACKGROUND: With the introduction of integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy, persons living with HIV have a potent new treatment option. Recently, providers at our large treatment clinic noted weight gain in several patients who switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). In this study, we evaluated weight change in patients with sustained virologic suppression who switched from EFV/TDF/FTC to an INSTI-containing regimen. METHODS: We performed a retrospective observational cohort study among adults on EFV/TDF/FTC for at least 2 years who had virologic suppression. We assessed weight change over 18 months in patients who switched from EFV/TDF/FTC to an INSTI-containing regimen or a protease inhibitor (PI)-containing regimen versus those on EFV/TDF/FTC over the same period. In a subgroup analysis, we compared patients switched to DTG/ABC/3TC versus raltegravir- or elvitegravir-containing regimens. RESULTS: A total of 495 patients were included: 136 who switched from EFV/TDF/FTC to an INSTI-containing regimen and 34 switched to a PI-containing regimen. Patients switched to an INSTI-containing regimen gained an average of 2.9 kg at 18 months compared with 0.9 kg among those continued on EFV/TDF/FTC (P = 0.003), whereas those switched to a PI regimen gained 0.7 kg (P = 0.81). Among INSTI regimens, those switched to DTG/ABC/3TC gained the most weight at 18 months (5.3 kg, P = 0.001 compared with EFV/TDF/FTC). CONCLUSION: Adults living with HIV with viral suppression gained significantly more weight after switching from daily, fixed-dose EFV/TDF/FTC to an INSTI-based regimen compared with those remaining on EFV/TDF/FTC. This weight gain was greatest among patients switching to DTG/ABC/3TC.
BACKGROUND: With the introduction of integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy, persons living with HIV have a potent new treatment option. Recently, providers at our large treatment clinic noted weight gain in several patients who switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). In this study, we evaluated weight change in patients with sustained virologic suppression who switched from EFV/TDF/FTC to an INSTI-containing regimen. METHODS: We performed a retrospective observational cohort study among adults on EFV/TDF/FTC for at least 2 years who had virologic suppression. We assessed weight change over 18 months in patients who switched from EFV/TDF/FTC to an INSTI-containing regimen or a protease inhibitor (PI)-containing regimen versus those on EFV/TDF/FTC over the same period. In a subgroup analysis, we compared patients switched to DTG/ABC/3TC versus raltegravir- or elvitegravir-containing regimens. RESULTS: A total of 495 patients were included: 136 who switched from EFV/TDF/FTC to an INSTI-containing regimen and 34 switched to a PI-containing regimen. Patients switched to an INSTI-containing regimen gained an average of 2.9 kg at 18 months compared with 0.9 kg among those continued on EFV/TDF/FTC (P = 0.003), whereas those switched to a PI regimen gained 0.7 kg (P = 0.81). Among INSTI regimens, those switched to DTG/ABC/3TC gained the most weight at 18 months (5.3 kg, P = 0.001 compared with EFV/TDF/FTC). CONCLUSION: Adults living with HIV with viral suppression gained significantly more weight after switching from daily, fixed-dose EFV/TDF/FTC to an INSTI-based regimen compared with those remaining on EFV/TDF/FTC. This weight gain was greatest among patients switching to DTG/ABC/3TC.
Authors: John R Koethe; Mohammed I Limbada; Mark J Giganti; Christopher K Nyirenda; Lloyd Mulenga; C William Wester; Benjamin H Chi; Jeffrey S Stringer Journal: AIDS Date: 2010-08-24 Impact factor: 4.177
Authors: Bianca Yuh; Janet Tate; Adeel A Butt; Kristina Crothers; Matthew Freiberg; David Leaf; Mary Logeais; David Rimland; Maria C Rodriguez-Barradas; Christopher Ruser; Amy C Justice Journal: Clin Infect Dis Date: 2015-03-11 Impact factor: 9.079
Authors: J C Melchior; G Raguin; A Boulier; E Bouvet; D Rigaud; S Matheron; E Casalino; J L Vilde; F Vachon; J P Coulaud Journal: Am J Clin Nutr Date: 1993-05 Impact factor: 7.045
Authors: D C Macallan; C Noble; C Baldwin; S A Jebb; A M Prentice; W A Coward; M B Sawyer; T J McManus; G E Griffin Journal: N Engl J Med Date: 1995-07-13 Impact factor: 91.245
Authors: Risa M Hoffman; Caitlin Newhouse; Brian Chu; Jeffrey S A Stringer; Judith S Currier Journal: Curr HIV/AIDS Rep Date: 2021-01-05 Impact factor: 5.071
Authors: Emily P Hyle; Justine A Scott; Paul E Sax; Lucia R I Millham; Caitlin M Dugdale; Milton C Weinstein; Kenneth A Freedberg; Rochelle P Walensky Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 9.079
Authors: David R Bakal; Lara E Coelho; Paula M Luz; Jesse L Clark; Raquel B De Boni; Sandra W Cardoso; Valdilea G Veloso; Jordan E Lake; Beatriz Grinsztejn Journal: J Antimicrob Chemother Date: 2018-08-01 Impact factor: 5.790
Authors: Jordan E Lake; Kunling Wu; Sara H Bares; Paula Debroy; Catherine Godfrey; John R Koethe; Grace A McComsey; Frank J Palella; Katherine Tassiopoulos; Kristine M Erlandson Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 9.079